New Hampshire Trust Boosts Merck Holdings to $4.97 Million

New Hampshire Trust has increased its investment in Merck & Co., Inc. (NYSE: MRK) by 10.2% during the third quarter of 2023, as detailed in its recent 13F filing with the Securities and Exchange Commission (SEC). The firm now holds 59,215 shares of Merck’s stock, having acquired an additional 5,471 shares during this period. This investment now represents approximately 1.0% of New Hampshire Trust’s overall portfolio, making it the trust’s 26th largest position.

As of the latest filing, New Hampshire Trust’s holdings in Merck are valued at $4.97 million. This adjustment reflects a broader trend, as other institutional investors have also been active in Merck’s stock. For example, Legend Financial Advisors Inc. acquired a stake valued at $25,000 in the second quarter, while Kilter Group LLC purchased shares worth about $27,000. Additionally, Bare Financial Services Inc. increased its position by 51.9%, now holding 366 shares valued at $29,000.

Market Performance and Dividends

Merck’s stock has shown resilience, opening at $106.90 on a recent trading day, marking a 0.4% increase. The company boasts a market capitalization of $265.33 billion, with a price-to-earnings (P/E) ratio of 14.12 and a beta of 0.29. Merck’s shares have fluctuated, reaching a twelve-month low of $73.31 and a high of $107.05.

In a significant development for shareholders, Merck announced a quarterly dividend of $0.85 per share, set to be paid on January 8, 2024. This represents an increase from the previous quarterly dividend of $0.81 and corresponds to an annualized dividend of $3.40, yielding 3.2%. The record date for this dividend is December 15, 2023, with a payout ratio currently at 44.91%.

Insider Activity and Analyst Ratings

In other news, Executive Vice President David Michael Williams sold 8,614 shares of Merck’s stock on November 3 for an average price of $83.59, totaling approximately $720,044.26. This transaction reduced his ownership by 25.95%, leaving him with 24,578 shares valued at around $2,054,475.02. Insider ownership currently stands at 0.13% of the total shares.

On the analyst front, several firms have recently updated their ratings on Merck. Wells Fargo & Company upgraded the stock from “equal weight” to “overweight,” raising the target price from $90.00 to $125.00. Bank of America also increased its price objective from $105.00 to $120.00, issuing a “buy” rating. Conversely, Berenberg Bank downgraded the stock from “buy” to “hold,” lowering the target price from $100.00 to $90.00.

According to MarketBeat.com, Merck currently holds a consensus rating of “Hold,” with eight analysts$110.13.

Merck & Co., Inc., a leading global biopharmaceutical company, is known for its extensive portfolio that includes prescription medicines, vaccines, and biologic therapies. Among its notable products are the cancer immunotherapy Keytruda and the HPV vaccine Gardasil, showcasing the company’s commitment to addressing various health challenges.